Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application, 39667 [2010-16897]

Download as PDF Federal Register / Vol. 75, No. 132 / Monday, July 12, 2010 / Notices is also available on the CPSC Web site at http://www.cpsc.gov. DEPARTMENT OF DEFENSE Dated: July 6, 2010. Todd A. Stevenson, Secretary, Consumer Product Safety Commission. Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application [FR Doc. 2010–16918 Filed 7–9–10; 8:45 am] ACTION: DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application Department of the Army, DoD. Notice. AGENCY: ACTION: erowe on DSK5CLS3C1PROD with NOTICES SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent 7,632,659, which issued on December 15, 2009, entitled ‘‘Use of Shigella Invaplex to Transport Functional Proteins and Transcriptionally Active Nucleic Acids Across Mammalian Cell Membranes In Vitro and In Vivo,’’ and U.S. Patent Application Serial No. 12/ 563,794, entitled ‘‘Use of Shigella Invaplex to Transport Functional Proteins and Transcriptionally Active Nucleic Acids Across Mammalian Cell Membranes In Vitro and In Vivo,’’ filed September 21, 2009. U.S. Patent Application Serial No. 12/563,794 is a continuation application of U.S. Patent 7,632,659. Foreign rights are also available for licensing (PCT/US2004/ 039100). The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The inventions relate to the use of Invaplex to transport materials, including functional proteins and biologically active nucleic acids, across eukaryotic cell membranes. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16889 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P VerDate Mar<15>2010 14:19 Jul 09, 2010 Department of the Army, DoD. Notice. AGENCY: BILLING CODE 6355–01–P Jkt 220001 SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/727,486, entitled ‘‘Artificial Invaplex,’’ filed March 27, 2007. Foreign rights are also available for licensing (PCT/US2007/ 007482). The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to an artificial invasin complex hat can facilitate the transport of biomolecules, therapeutics and antibiotics across cell membranes in a manner similar to native Shigella Invaplex. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16897 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application Department of the Army, DoD. Notice. AGENCY: ACTION: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 12/149,076, entitled ‘‘Combinations of Gene Deletions for Live Attenuated Shigella Vaccine Strains,’’ filed April 25, 2008. Foreign rights are also available for licensing (PCT/US2008/005342). The United States Government, as SUMMARY: PO 00000 Frm 00016 Fmt 4703 Sfmt 4703 39667 represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates generally to Shigella vaccine, strains, their use in vaccines, and the methods for treatment of dysentery. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–16894 Filed 7–9–10; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Department of the Army Availability for Non-Exclusive or Partially Exclusive Licensing of a U.S. Patent Application Department of the Army, DoD. Notice. AGENCY: ACTION: SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Patent Application Serial No. 11/132,199, entitled ‘‘Construction of Live Attenuated Shigella Vaccine Strains that Express CFA/I Antigens (CFAB and CFAE) and the B Subunit of Heat-Labile Enterotoxin (LTB) From Enterotoxigenic E. Coli,’’ filed May 19, 2005. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to materials and methodologies for preparing multivalent vaccines, recombinant DNA expression E:\FR\FM\12JYN1.SGM 12JYN1

Agencies

[Federal Register Volume 75, Number 132 (Monday, July 12, 2010)]
[Notices]
[Page 39667]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-16897]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive or Partially Exclusive Licensing 
of a U.S. Patent Application

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Patent Application Serial No. 11/727,486, 
entitled ``Artificial Invaplex,'' filed March 27, 2007. Foreign rights 
are also available for licensing (PCT/US2007/007482). The United States 
Government, as represented by the Secretary of the Army, has rights to 
this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to an artificial 
invasin complex hat can facilitate the transport of biomolecules, 
therapeutics and antibiotics across cell membranes in a manner similar 
to native Shigella Invaplex.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010-16897 Filed 7-9-10; 8:45 am]
BILLING CODE 3710-08-P